Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | CASP3 | P42574 | 2/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
| ▸ | ACHE | P22303 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382160 | 1.00 | MAOB (1.00) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL16334580 | 0.89 | NPC1 (0.83) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL16334329 | 0.88 | NPC1 (1.00) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL120325 | 0.87 | MAOB (0.77) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL122823 | 0.87 | MAOB (0.77) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL24323053 | 0.87 | RAB9A (0.77) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL28444530 | 0.87 | MAOB (1.00) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL16334073 | 0.87 | MAOB (0.80) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL29724368 | 0.87 | MAOB (1.00) | MAOBRAB9ANPC1MAOACASP3 | |
| SCHEMBL16580069 | 0.87 | NPC1 (0.79) | MAOBRAB9ANPC1MAOACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107722169-B | Macromolecular chain transfer agent containing coumarin fluorescent group and preparation method thereof | 厦门大学 | 2019-12-20 | — | — | CN | claimed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| EP-3946604-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | The Scripps Research Institute (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020205683-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-08 | — | — | WO | disclosed |
| CN-107722169-B | Macromolecular chain transfer agent containing coumarin fluorescent group and preparation method thereof | 厦门大学 | 2019-12-20 | — | — | CN | disclosed |
| CN-107722169-B | Macromolecular chain transfer agent containing coumarin fluorescent group and preparation method thereof | 厦门大学 | 2019-12-20 | — | — | CN | disclosed |
| US-9695193-B2 | Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695193-B2 | Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695193-B2 | Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2611912-B1 | NOVEL MONOOXYGENASE VARIANTS | BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | UNIV COLUMBIA (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | UNIV COLUMBIA (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | UNIV COLUMBIA (US) | 2016-05-05 | — | — | US | disclosed |
| WO-2014210319-A2 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE 1 AS ANTI-PARASITIC COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20130225870-A1 | METHOD OF SYNTHESIZING SUBSTITUTED 2-ALKYL PHENOLS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225870-A1 | METHOD OF SYNTHESIZING SUBSTITUTED 2-ALKYL PHENOLS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2426198-A1 | Cytochrome P450 monooxygenase variants | B.R.A.I.N. Biotechnology Research And Information Network AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012026931-A1 | METHOD OF SYNTHESIZING SUBSTITUTED 2-ALKYL PHENOLS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | SLC29A1, SLC29A2, SLC28A1 | MAOB 2541/4885RAB9A 1709/4885NPC1 144/4885 |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | TTR, MAP1LC3B, SAAL1 | MAOB 3893/4885RAB9A 3384/4885NPC1 2877/4885 |
| US-20130225870-A1 | METHOD OF SYNTHESIZING SUBSTITUTED 2-ALKYL PHENOLS | CYP4B1, CYP4A11, CYP4X1 | MAOB 420/4885RAB9A 1789/4885NPC1 1922/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | MAOB 3893/4885RAB9A 3384/4885NPC1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.